Agilent Technologies (NYSE:A) Earns Neutral Rating from Analysts at UBS Group

UBS Group started coverage on shares of Agilent Technologies (NYSE:A) in a report issued on Wednesday morning, MarketBeat.com reports. The brokerage issued a neutral rating and a $165.00 target price on the medical research company’s stock.

A has been the topic of several other reports. Sanford C. Bernstein lifted their target price on shares of Agilent Technologies from $155.00 to $180.00 and gave the stock an “outperform” rating in a research note on Thursday, August 27th. Robert W. Baird increased their target price on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 26th. Citigroup lifted their price target on shares of Agilent Technologies from $185.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. JPMorgan Chase & Co. lifted their price objective on Agilent Technologies from $180.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Finally, Royal Bank Of Canada lifted their target price on shares of Agilent Technologies from $155.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.33.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $146.91 on Wednesday. The stock has a market cap of $41.42 billion, a price-to-earnings ratio of 28.92, a P/E/G ratio of 2.18 and a beta of 1.24. Agilent Technologies has a 1-year low of $108.35 and a 1-year high of $163.75. The stock’s 50-day moving average is $143.71 and its 200 day moving average is $128.62. The company has a current ratio of 2.05, a quick ratio of 1.56 and a debt-to-equity ratio of 0.50.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.13. The firm had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.45%. The business’s quarterly revenue was up 8.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, sell-side analysts anticipate that Agilent Technologies will post 6.2 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Mikael Dolsten sold 634 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at approximately $745,395.12. The trade was a 11.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Core Wealth Advisors LLC purchased a new stake in shares of Agilent Technologies during the 4th quarter valued at about $26,000. SHP Wealth Management bought a new stake in Agilent Technologies during the 4th quarter valued at $26,000. Navalign LLC bought a new stake in shares of Agilent Technologies in the fourth quarter valued at about $27,000. Cedar Mountain Advisors LLC bought a new stake in shares of Agilent Technologies in the 1st quarter valued at about $27,000. Finally, Markowski Investments purchased a new stake in shares of Agilent Technologies in the 2nd quarter worth approximately $27,000. Hedge funds and other institutional investors own 87.41% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc is a global provider of analytical instruments, laboratory software, consumables and services used by organizations in the life sciences, diagnostics, pharmaceutical, chemical, environmental and food industries. Its solutions help customers analyze the composition and quality of substances, develop and manufacture products, and conduct research and testing.

The company’s offerings include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy and atomic analysis equipment, automated electrophoresis systems, laboratory informatics software, columns and other consumables.